External innovation holds the key for long-term growth
03/12/20 -"Despite the generic erosion of Somatuline, Ipsen is targeting +2-5% sales growth p.a. until FY24, driven by the maximisation of the value of Cabometyx, Onivyde, Palovarotene, Decapeptyl and Dysport ..."
Pages
59
Language
English
Published on
03/12/20
You may also be interested by these reports :
26/01/21
Since our last Teaser in November 2019, it has been a roller-coaster ride for Sanofi (Buy, France). While an impressive mid-term growth strategy ...
30/12/20
With UK’s emergency use approval for Astra-Oxford’s COVID-19 vaccine candidate, the sentiment around Astra’s share price should improve finally. ...
23/12/20
Since our last endorsement in April 2020, it has been a seesaw ride for the generic drugs manufacturer, Hikma (Add, UK). While the reiteration of its ...
21/12/20
Bayer placed ~75% of its 72.9 million Elanco shares with institutional investors for USD30.25 per share, which is below the USD31.55 per share Bayer ...